CD276 and breast cancer: For the matched cases stratified according to breast cancer subtype (ER+, HER2+, TNBC), we observed an equal proportion of cases with C+M B7-H3 expression and that membrane-only expression increased in the BrM cases in each subtype (Figure 5b).